14 & 15 June 2023 Palexpo, Geneva

Travere Therapeutics new drug, FILSPARI, has been approved by the FDA

Travere Therapeutics, the biopharmaceutical company determined to develop treatment for people with rare diseases, have developed a drug called FILSPARI, that has been approved by the FDA. The medication is used to reduce proteinuria (protein in urine), in patients, particularly adults, that suffer with primary IgA nephropathy (IgAN).

IgAN is a rare kidney disease caused by the progressive build up in the kidney of immunoglobulin A (IgA), a protein that help the immune system fight infections. The over production of IgA can cause proteinuria, hematuria and a gradual loss of kidney function. Its is a type of primary glomerulonephritis, that is well-established as the most common variety found globally and is a significant contributing factor to kidney failure caused by glomerular disease.

FILSPARI is an oral drug which must be taken on a daily basis to prevent rapid disease progression. It is the first and only non-immunosuppressive therapy approved for this disease.

Follow us:

Share this article: